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Patients receiving psychiatric medication, like the antipsychotic drug haloperidol, are at an increased risk
of sudden cardiac death (SCD). Haloperidol blocks the cardiac rapidly-activating delayed rectifier potas-
sium current, thereby increasing electrical dispersion of repolarization which can potentially lead to
arrhythmias. Whether these patients are also at a higher risk to develop SCD during an acute myocardial
infarction (AMI) is unknown. AMI locally shortens action potential duration, which might further increase
repolarization dispersion and increase the risk of arrhythmia in the presence of haloperidol compared to
without. Our aim was to test whether treatment with haloperidol implies an increased risk of SCD when
eventually experiencing AMI. Twenty-eight female Danish Landrace pigs were randomized into three
groups: low dose haloperidol (0.1 mg/kg), high dose (1.0 mg/kg) or vehicle-control group. One hour after
haloperidol/vehicle infusion, AMI was induced by balloon-occlusion of the mid-left anterior descending
coronary artery and maintained for 120 min, followed by 60 min of reperfusion. VF occurred during
occlusion in 7/11 pigs in the control group, 3/11 in the low dose (p = 0.198) and 2/6 in the high dose group
(p = 0.335). High dose haloperidol significantly prolonged QT, and reduced heart rate, vascular resistance
and blood pressure before and during AMI. Premature ventricular contractions in phase 1b during AMI
were reduced with high dose haloperidol. AMI-induced arrhythmia was not aggravated in pigs with
haloperidol treatment. Our results do not suggest that AMI is contributing to the excess mortality in
patients treated with antipsychotic drugs seen in epidemiological studies.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of sudden cardiac death (SCD) is increased dra-
matically in psychiatric patients compared to the background pop-
ulation [1]. We have previously found a four-fold increase of SCD in
young patients with prior psychiatric hospitalization in a nation-
wide Danish study [2]. The excess mortality in psychiatric diseasesare multifactorial, including environmental factors, life-style, and
psychopharmacological treatment [3]. Medication is thought to
be a risk factor and a quarter of all patients in the age group of
1–49 years suffering from SCD due to coronary artery disease
had a positive toxicology for psychiatric medication [4]. A number
of psychopharmacological drugs are known to block cardiac ion
channels, in particular the delayed rectifier potassium channel
hERG1, conducting IKr, thereby prolonging cardiac repolarization.
This leads to a prolonged QT interval, a risk factor for torsades de
pointes (TdP) tachycardia and, as a final consequence, SCD [3].
Haloperidol is a widely used first generation (typical) antipsy-
chotic drug, blocking the D2 dopamine receptor family. It is mainly
2 S.M. Sattler et al. / IJC Heart & Vasculature 26 (2020) 100455used to treat schizophrenia and agitation, but is also the preferred
antipsychotic compound for the treatment of delirium [5,6]. Little
is known on whether or to what extent haloperidol’s arrhythmic
potential is modulated by potential proarrhythmic events, like
acute myocardial infarction (AMI). AMI is the leading cause of
SCD in the Western world [7] with more than 10% of all AMI
patients developing ventricular fibrillation (VF) in the early phase
(within minutes after symptom onset) [8], caused by proarrhyth-
mic alterations of a variety of electrophysiological parameters
[9]. Further, signs of AMI in the absence of symptoms were
detected in greater than 40% of SCD victims that had no history
of coronary artery disease [10].
We hypothesized that patients taking a first generation (typical)
antipsychotic drug, like haloperidol, are at higher risk to develop
VF when eventually experiencing AMI and that (silent) AMI con-
tributes to the excess mortality seen in epidemiological studies.
We expected effects on both, electrophysiological substrate and
triggers. The substrate might be changed by an increase in ventric-
ular dispersion of repolarization as AMI locally shortens action
potential duration (APD) in a ventricle with globally prolonged
APD due to haloperidol treatment. This could facilitate ventricular
arrhythmias and consecutive VF.
Our aim was to test acute administration of a low dose of
0.1 mg/kg haloperidol (as recommended in chronic treatment)
and a high dose of 1.0 mg/kg haloperidol (as often seen in treat-
ment of acutely agitated patients) one hour before the onset of
AMI in a porcine model. We aimed to assess its effect on arrhyth-
mias including VF, changes in cardiac repolarization, and hemody-
namic parameters during AMI and reperfusion. With this study weECG
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Fig. 1. Experimental setup and representative traces. A: Experimental setup. Pigs were m
echocardiography, haloperidol (0.1 mg/kg or 1.0 mg/kg) or saline control was infused 60
artery (LAD) was kept occluded for 120 min, followed by a 60 min reperfusion pha
monophasic action potentials (LV-MAP), right ventricular (RV) MAP, arterial blood press
before and after infusion of haloperidol (1.0 mg/kg), at baseline and during occlusion. Infu
QT interval. AMI resulted in ST elevation and local MAP shortening. PTCA: percutaneous
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psychiatric patients treated with antipsychotic drugs.2. Material and methods
Twenty-eight female Danish Landrace pigs (mean body weight
52 kg, range 47–57 kg, mean heart weight 250 g, range 200–
295 g) were randomized to a control (n = 11), a low dose
(n = 11), or a high dose (n = 6) intervention group. Only female ani-
mals were included as the risk for TdP and VF during AMI is higher
with female gender [11]. Fewer pigs were randomized into the
high dose group as an excess mortality during AMI was expected.
Randomization was done the day before the experiment using a
randomization table. Persons who carried out coronary occlusion
and data analysis were blinded regarding randomization results.
All experiments were performed under the animal license number
(2015-15-0201-00613) authorized by the Danish Animal Inspec-
torate in accordance with EU legislations for animal protection
and care.2.1. Procedure
The experimental procedure is depicted in Fig. 1A. Pigs were
premedicated with tiletamin/zolazepam, xylazine, ketamine,
butorphanol, methadone, intubated and ventilated (tidal volume
8 ml/kg, frequency 14 min1, and inspirational concentration of
oxygen 0.3). Ventilation was adjusted when necessary to keep
blood gas parameters at normal levels. Anesthesia was maintained75
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se. B: Representative tracings depicting electrocardiogram (ECG), left ventricular
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sion of haloperidol decreased heart rate and blood pressure and prolonged MAP and
transluminal coronary angioplasty. Black bar: 1 s.
penhagen from ClinicalKey.com by Elsevier on May 01, 2020.
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12.5 mg/h/kg (Propolipid 10 mg/ml, Fresenius Kabi AB, Uppsala,
Sweden) and fentanyl 5 mg/h/kg (Fentanyl-Hameln 50 mg/ml,
Hameln, Germany).
A 22 gauge arterial catheter was placed in the right femoral
artery (Arrow arterial catherization set, SAC-01222, Arrow Interna-
tional Inc., Reading, USA) to measure arterial blood pressure. A
mid-side 8 cm long cut was performed on the ventral side of the
neck and two venous and two arterial 8 french sheaths (Check-
Flo Performer Introducer, Cook Inc., Bloomington, USA) were
placed. Electrocardiogram (ECG) was recorded in x-y-z configura-
tion during the whole experiment using three BioAmps (AD Instru-
ments, Dunedin, New Zealand). To measure pulmonary artery
pressure and cardiac output (CO) a Swan-Ganz catheter (Swan-
Ganz VIP, Edwards Lifesciences, Irvine, USA) was placed into the
pulmonary artery.
Haloperidol (0.1 or 1.0 mg/kg) or saline as control was given
according to randomization over 10 min, 60 min before AMI was
induced via the atrial lumen of the Swan Ganz catheter. After a sta-
bilization phase of 20 min, Franz electrodes (Easy MAP, Föhr Med-
ical Instruments GmbH, Seeheim, Germany) to record monophasic
action potentials (MAP) were placed at the free wall of the right
and the infarcted area (apico-septal) of the left ventricle (LV).
An angiogram was performed using a Judkin’s Left 3.5, 6 French
catheter (Launcher, Medtronic Inc. Minneapolis, USA), positioned
into the left main coronary artery. Following that, a balloon (3.5
 12 mm, TREK, Abbott Vascular, Santa Clara, USA) was positioned
into the left anterior descending artery at its mid position (after
take-off of the first diagonal branch). A baseline echocardiography
and CO measurement was done and the balloon was inflated with
12 bar and occlusion was confirmed by angiogram. Occlusion was
maintained for 120 min followed by 60 min of reperfusion. Pigs
were euthanized at the end of the experiment by inducing VF via
burst pacing (50 Hz, 3 s, 7 V output).
2.2. Electrophysiology and hemodynamics
ECG, MAP and hemodynamic (blood pressure, central venous
pressure and pulmonary artery pressure) were recorded continu-
ously at a 2 kHz sampling rate (built-in hardware filter set to
0.1–2000 Hz) using AD Instruments PowerLab 16/30 (AD Instru-
ments, Dunedin, New Zealand). RR, PQ, QT, corrected QT (QTc =
(QT/RR)1/3), and Tpeak dispersion intervals as well as vector magni-
tude of ST elevation 60 s after the J point (STVM, with STVM=(STx2 +-
STy
2 + STz
2)1/2) and QRS duration. Parameters were manually
measured before and after drug injection, before coronary occlu-
sion and during occlusion at time points 1, 3, 5, 10, 15, 20, 30
and every 15 min during occlusion and reperfusion.
CO was measured by means of thermodilution via the Swan
Ganz catheter before and after drug injection, before occlusion,
and every 15 min during reperfusion and occlusion. Along with
CO, blood pressure, central venous pressure and pulmonary artery
pressure were measured. Systemic vascular resistance (SVR) was
calculated according to SVR = 80 (mean arterial pressure  central
venous pressure)/CO.
PVCs were manually counted for every minute and analyzed
separately for their distinct peaks of occurrence, phase 1a and 1b
[9]. More than three consecutive PVCs with a heart rate greater
than 100 min1 were defined as non-sustained ventricular tachy-
cardia (VT) or VT when lasting for more than 30 s.
MAP recordings were used to measure APD duration at 90% of
repolarization (MAPD90) in the infarcted and non-infarcted area.
Measurements were performed before occlusion and during the
first 20 min of AMI. During the procedure, no repositioning of
MAP electrodes was performed to avoid induction of arrhythmias
or VF. Changes from baseline (DMAPD90) and MAPD90 dispersionDownloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. Cbetween the two electrodes (|MAPD90,RV  MAPD90,LV|) were
calculated.
2.3. Dominant frequency analysis
Dominant frequency (DF) of VF was determined using fast Four-
ier transform (FFT). Analysis was performed using MATLAB (Ver-
sion R2019a, MatWorks Inc.). ECG was imported into MATLAB
and a FFT was performed using a 6-second sliding window with
3 s overlap. The DF was extracted from each FFT spectrum. DF val-
ues were compared in the first 30 s of the VF episode. Spontaneous
VF episodes (n = 7, 3 and 2 for control, low dose and high dose
group, respectively) and the combination of spontaneous and
induced VF episodes (n = 11, 11 and 6) were analyzed.
2.4. Short-term variability
Beat-to-beat variation of repolarization (BVR) measured as
short-term variability (STV) according to Thomsen et al. [12] was
performed on MAP recordings in the LV. MAP duration were auto-
matically analyzed and manually controlled using a custom-made
software in MATLAB. Thirty consecutive beats in sinus rhythm
without ectopic beats were selected for analysis at baseline (5)
and upon 15 min of AMI. Additionally, in the high dose haloperidol
group MAP recordings before and after drug-infusion were avail-
able and analyzed (60 and 50, respectively). MAP duration at
80% of repolarization (MAPD80) was used to calculate short-term
variability (STV) according to
STV ¼
X30
n¼1
MAPDnþ1 MAPDnj j= 30p2ð Þ2.5. Echocardiography
Image acquisition was performed using an iE33 echocardiogra-
phy system (Philips Healthcare, Amsterdam, The Netherlands)
equipped with a S5-1 transducer (3.5 MHz, Philips Healthcare,
Amsterdam, The Netherlands). A modified apical four-chamber
view was performed using a trans-diaphragmal approach at base-
line and at 0, 7, 15, and 30 min of occlusion. Tissue Doppler imag-
ing was used to measure average s’-wave velocity. All
examinations were stored externally and transferred to the
vendor-specific workstation Philips Xcelera for post-processing
analyzing. LV ejection fraction (LVEF) was calculated by one expe-
rienced reader using Simpson’s method of discs by manually delin-
eating the endocardial border in end-systole and end-diastole.
2.6. Statistics
Statistical analysis was done in R (R Core Team, R Foundation
for Statistical Computing, Vienna, Austria). Data are shown as
mean values and standard error of the mean. Electrophysiological
and hemodynamic parameters as well as echocardiographic mea-
surements were compared using a permutation test. Comparisons
were performed to assess the effect of haloperidol before AMI
(t = 50 to 5) and during occlusion (t = 1 to 15 for hemodynamic
parameters, t = 1 to 20 for electrophysiological parameter). Free-
dom from VF was compared using a two-tailed permutation test
based on the Log rank test statistic and an exact Fisher test. We
considered a p-value of < 0.05 as statistically significant.
3. Results
Representative traces of ECG, MAP and hemodynamic record-
ings are depicted in Fig. 1B.hagen from ClinicalKey.com by Elsevier on May 01, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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Temporal changes of the ECG parameters are shown for low and
high dose haloperidol and control group in Fig. 2. Pigs treated with
haloperidol had a trend towards longer RR intervals in a dose-
dependent manner before AMI (control: 684 ± 36 ms, low dose:
773 ± 71 ms, high dose: 877 ± 71 ms; low dose versus controlR
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Fig. 2. Electrocardiogram (ECG) parameters. A: RR intervals with a trend towards
longer RR interval for the high dose group before and during the first 20 min of AMI.
B: Infarct related changes in QRS width were comparable in the three groups. C and
D: High dose haloperidol prolonged QT with similar effects for QTc while no effect
was seen with low dose haloperidol. E: ST elevation was comparable for all three
groups during occlusion and reperfusion. Gray bar indicates treatment with low
dose haloperidol, high dose haloperidol or vehicle. Significance level: high dose vs.
control, * p < 0.05, ** p < 0.01.
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20 min of AMI (control: 686 ± 35 ms, low dose: 713 ± 54 ms, high
dose: 784 ± 55 ms; low dose versus control p = 0.331, high dose
versus control p = 0.047, Fig. 2A). QRS complexes showed a tran-
sient widening during AMI, comparable in the three groups (low
dose versus control p = 0.58, high dose versus control p = 0.139,
Fig. 2B). QT intervals were prolonged in the high dose group
(before AMI: control: 339 ± 13 ms, low dose: 334 ± 11 ms, high
dose: 382 ± 10 ms; high dose versus control p = 0.007, during
AMI: control: 330 ± 15 ms, low dose: 321 ± 12 ms, high dose:
379 ± 12 ms; high dose versus control p = 0.012; Fig. 2C). Similar
behavior was observed after correcting for heart rate (before
AMI: control: 385 ± 11 ms, low dose: 374 ± 11 ms, high dose:
402 ± 16 ms; during AMI: control: 375 ± 15 ms, low dose:
358 ± 11 ms, high dose: 421 ± 10 ms; Fig. 2D). No QT prolongation
was seen in the low dose group (low dose versus control p = 0.871
at baseline, low dose versus control p = 0.788 during AMI). Tpeak
dispersion increased with high dose haloperidol treatment (before
AMI: control: 8 ± 2 ms, low dose: 7 ± 2 ms, high dose: 10 ± 3 ms;
during AMI (t = 5): control: 18 ± 5 ms, low dose: 14 ± 4 ms, high
dose: 58 ± 6 ms; during AMI (t = 20): control: 14 ± 5 ms, low dose:
20 ± 6 ms, high dose: 49 ± 6 ms).
All pigs had ST elevation after induction of AMI that occurred in
three peaks, two during occlusion (approximately at 10 and 45 min
after onset of AMI) and one immediately after reperfusion
occurred. ST elevation, measured as STVM was not changed by
low or high dose haloperidol treatment (p = 0.102 and p = 0.719,
respectively, Fig. 2E).
In order to investigate effects of haloperidol on the ventricular
electrophysiology we analyzed MAPD90 and the change of MAPD90
compared to baseline (DMAPD90) for the infarcted and non-
infarcted area. MAPD90 was prolonged at baseline in the high dose
haloperidol group (high dose versus control p = 0.007, Fig. 3A). AMI
caused a shortening of MAPD90 in the infarcted area, but DMAPD90
was similar for low and high dose haloperidol and control group
(low dose versus control p = 0.504, high dose versus control
p = 0.465, Fig. 3B). No changes with AMI occurred in the non-
infarcted area (Fig. 3A). Dispersion of MAPD90 between RV and
LV showed only a tendency towards higher dispersion in the low
dose and high dose haloperidol group at baseline: 10 ± 3 ms,
17 ± 4 ms, and 15 ± 4 ms for control, low dose, and high dose group,
respectively (low dose versus control p = 0.258, high dose versus
control p = 0.468).
STV, a parameter predictive of TdP slightly increased with high
dose haloperidol infusion from 0.7 ± 0.2 ms to 1.0 ± 0.3 ms, but
returned to baseline before AMI was induced. AMI increased STV
within 15 min of occlusion, similar in the three groups (baseline
0.5 ± 0.1 ms; 15 min of AMI 1.1 ± 0.5 ms, 2.1 ± 0.5 ms and 2.0 ± 1.
0 ms for control, low dose, and high dose haloperidol group,
respectively; low dose versus control p = 0.226 and high dose ver-
sus control p = 0.488, Fig. 4).
3.2. Hemodynamics
Effects of haloperidol on SVR, mean arterial blood pressure,
heart rate, and CO were measured at baseline and during AMI
(Fig. 5). Haloperidol led to vasodilatation, measured as decreased
SVR in the high dose group. A drop in SVR was observed before
AMI was induced (low dose versus control p = 0.738, high dose ver-
sus control p = 0.013) and during the first 15 min of AMI (low dose
versus control p = 0.125, high dose versus control p = 0.014,
Fig. 5A). This resulted in a dose-dependent drop in blood pressure
before AMI was induced (low dose versus control p = 0.330, high
dose versus control p < 0.001) and during the first 15 min of AMI
(low dose versus control p = 0.125, high dose versus control
p = 0.004, Fig. 5B). CO was not affected by haloperidol treatmentpenhagen from ClinicalKey.com by Elsevier on May 01, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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S.M. Sattler et al. / IJC Heart & Vasculature 26 (2020) 100455 5before AMI (low dose versus control p = 0.920, high dose versus
control p = 0.368) or during AMI (low dose versus control
p = 0.733, high dose versus control p = 0.662, Fig. 5D). In the high
dose group, CO increased due to higher heart rate after the first
30 min of AMI and led to an increase in arterial blood pressure
while SVR stayed unchanged.3.3. Arrhythmia
Arrhythmias during AMI were assessed for control and
haloperidol groups. The distribution of PVCs during myocardial
infarction is shown in Fig. 6A. The mean number of PVCs per min-
ute in phase 1a (2–15 min from occlusion; 4.3 ± 1.1, 3.2 ± 1.2,
6.7 ± 2.5; control, low dose, high dose) was neither statistically dif-
ferent for low dose versus control group (p = 0.492), nor for high
dose versus control group (p = 0.404). PVCs in phase 1b (16–
30 min from occlusion; 6.1 ± 1.2, 4.2 ± 1.1, 1.5 ± 0.7; control, low
dose, high dose) were reduced with high dose haloperidol
(p = 0.001), but not different for low dose and control (p = 0.26).
We did not observe non-sustained VT exceeding 10 beats or VT
during coronary occlusion. Reopening of the coronary occlusion led
to reperfusion arrhythmia, an idioventricular rhythm with cycle
lengths of approximately 500 ms or above, in all animals covering
the whole reperfusion period.
VF during AMI occurred in 27% (3/11), 33% (2/6), and 64% (7/11)
of pigs in low dose, high dose and control groups, respectively
(Fisher’s exact test: low dose versus control p = 0.198, high dose
versus control p = 0.335; Permutation test based on the Log rank
test statistic: low dose versus control p = 0.197, high dose versusDownloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. Ccontrol p = 0.122). Overall, VF occurred in 11 out of 12 cases
between 15 and 25 min after coronary occlusion was initiated
(Fig. 6B). DF during spontaneous VF was significantly lower in
the high dose haloperidol group (p = 0.037) compared to control
while no difference was observed with low dose treatment
(p = 0.668, Fig. 6C and 7A). When including animals with induced
VF at the end of the experiment the high dose haloperidol group
still had a lower DF (p = 0.043). No difference with low dose
haloperidol treatment compared to control was observed
(p = 0.450, Fig. 7B). None of the pigs had VF during the reperfusion
period. Hemodynamic characteristics of the individual pigs prior to
VF are given in Table 1.
Stratifying our results into pigs with and without VF revealed
trends towards possible characteristics that differ between these
groups (figure S1). Pigs that developed VF had a tendency towards
shorter RR, and QTpeak intervals, longer PQ, QRS, and Tpeak  Tend
intervals, as well as higher STVM. Hemodynamically, higher blood
pressure (diastolic, mean and systolic), and SVR was seen in pigs
with VF during AMI.3.4. Echocardiography
LVEF was measured along with CO to assess impairment of car-
diac function during AMI and decreased equally within the first
minutes of AMI in all groups (low dose versus control p = 0.998,
high dose versus control p = 0.790, Fig. 8B). Results from tissue
Doppler imaging showed a decrease in average s’-wave velocity
with AMI, comparable between the groups (low dose versus con-
trol p = 0.863, high dose versus control p = 0.967, Fig. 8C).4. Discussion
The aim of this study was to investigate the effect of haloperidol
on electrophysiological properties, arrhythmia, and hemodynamics
during AMI. AMI alone led to changes in RR, QRS, and STVM, short-
ening of MAPD90, increase in STV, drop in blood pressure and CO as
well as ventricular arrhythmias. Haloperidol (1.0 mg/kg), given one
hour prior to AMI prolonged RR, QT and QTc intervals and
decreased mean arterial blood pressure and SVR compared to
AMI alone. Further, MAPD90 was prolonged at baseline, with simi-
lar shortening to control during AMI. Haloperidol did not result in a
higher proportion of pigs developing VF during two hours of occlu-
sion and one hour of reperfusion, but on the contrary showed a
tendency towards lower VF incidence and fewer PVCs in phase 1b.
Treatment with antipsychotic drugs increase the risk of both
SCD and out-of-hospital cardiac arrest in a dose dependent mannerhagen from ClinicalKey.com by Elsevier on May 01, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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6 S.M. Sattler et al. / IJC Heart & Vasculature 26 (2020) 100455[13,14]. Certain risk factors have been suggested to contribute to
this excess mortality, like female gender, heart disease, concomi-
tant drug and high doses [11]. We sought to investigate whether
treatment with haloperidol increases the chance of experiencing
ventricular arrhythmia and subsequent VF during AMI.4.1. QT prolongation and dose dependence
High dose haloperidol treatment resulted in a prolongation of
QT-intervals that started ten minutes after infusion and QT-
intervals stayed prolonged following AMI. Low dose haloperidol
treatment or AMI did not affect QT interval significantly. QT pro-
longation and increased dispersion in repolarization that eventu-
ally lead to TdP are the suspected pro-arrhythmic mechanisms
underlying SCD in patients taking antipsychotic drugs. Many stud-
ies investigating those found only moderate or no QT prolongation
for haloperidol [15]. Vieweg et al. reviewed cases of QT prolonga-
tion focusing on elderly patients taking psychotropic drugs. In
many cases where psychotropic drugs led to QT prolongation,
higher drug doses than recommended were used [16]. Although
many patients with TdP have used haloperidol dosages of several
hundred mg daily or even more than one gram daily, some cases
occurred at lower doses, i.e. 9–35 mg [6]. Sugiyama et al. tested
three different doses of haloperidol (0.03, 0.3 and 3 mg/kg, infused
over 10 min) in a canine model and found effects on QT and QTc
starting at doses of 0.3 mg/kg [17]. In a porcine model, Tisdale
et al. did not detect a significant influence of haloperidol
(2–3.3 mg/kg) on heart rate, QRS duration or QTc interval [18].
We have used two different haloperidol doses in our experi-
ments. The dose of 0.1 mg/kg haloperidol, approximately 5 mg
per pig, was chosen since starting doses for moderate agitation in
humans are recommended to be 5 to 10 mg and this dose is known
to increase risk for SCD [5,13,19]. A high dose of 1.0 mg/kgDownloaded for Anonymous User (n/a) at BS - University of Co
For personal use only. No other uses without permissiohaloperidol, approximately 50 mg per pig, was used as high doses
are regularly used in clinics for acute management of delirium
[11,20].4.2. Arrhythmias and AMI moderated substrate and triggers
Our study did not show higher incidence rates of VF with
haloperidol compared to AMI alone. On the contrary, a tendency
towards fewer animals with VF was seen with haloperidol treat-
ment: Only 27% (3/11) of the pigs treated with low dose haloperi-
dol and 33% (2/6) treated with high dose haloperidol compared to
64% (7/11) in the control group, experienced VF. While no studies
in large animal models with ischemia and haloperidol exist, Davis
and Bigger reported the effects of thioridazine, another antipsy-
chotic drug and a potent hERG channel blocker, on VF during
AMI in dogs. Although thioridazine reduced heart rate and
decreased excitability in the ventricle without altering VF thresh-
old, an increased number of dogs experienced VF during AMI com-
pared to control [21]. In the context of haloperidol, Tisdal et al.
found that altering VF threshold in pigs after intravenous haloperi-
dol (2–3.3 mg/kg) treatment, was increased 15 min after infusion,
making an induction of VF more difficult [18]. In humans, Park et al.
reported an increased risk of in-hospital death in AMI patients with
acute delirium when treated with haloperidol compared to atypi-
cal antipsychotic drugs [22]. However, treatment in this cohort
study was started after AMI and patients with haloperidol treat-
ment before AMI were excluded in the analysis. This limits com-
parison with our data as electrophysiological properties change
considerably within the first days of AMI [9].
Arrhythmia can arise if a certain trigger hits an arrhythmogenic
substrate. AMI on the one side, can induce such proarrhythmic
conditions by local shortening of APD, slowing of conduction, trig-
gering of PVCs, increased sympathetic tone, and increased disper-penhagen from ClinicalKey.com by Elsevier on May 01, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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S.M. Sattler et al. / IJC Heart & Vasculature 26 (2020) 100455 7sion in activation and repolarization [9]. In cardiomyocytes, ische-
mia leads to an increase in outward potassium currents, a decrease
in sodium current and a depolarized resting membrane potential
[23].
Antipsychotic drugs on the other side, are likely to induce TdP
tachycardia when a high dispersion of repolarization is present
[24]. Simultaneously firing multiple foci generating early afterDownloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. Cdepolarizations are believed to underlie the generation of TdP.
Mechanisms underlying subsequent beats is thought to be reen-
try in a ventricle with high inhomogeneity of refractoriness
[25]. In patients, episodes of TdP are often described to happen
in situations of physical or emotional stress and are enhanced
by beta-adrenergic agonists [26]. Although not typically seen with
ischemia or AMI, short runs of TdP-like ventricular tachycardiahagen from ClinicalKey.com by Elsevier on May 01, 2020.
opyright ©2020. Elsevier Inc. All rights reserved.
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Table 1
Characteristics of ventricular fibrillation.
Prior to VF
HR (min1) BP (mmHg) Lactate (mmol/l) Time to VF (min)
Control 71 116/79 (91) 1.1 18
110 85/48 (60) 1.8 20
106 123/83 (96) 0.6 20
78 95/56 (69) 0.9 19
120 119/78 (92) 1.9 21
113 130/90 (103) 1.6 19
95 111/74 (86) 0.8 16
99 ± 6.5 111/73(85) ± 6/5(5) 1.2 ± 0.2 19 ± 0.6
Haloperidol 0.1 mg/kg 98 111/75 (87) 1.9 15
90 104/71 (82) 0.8 4
81 120/79 (93) 0.7 18
89 ± 4.0 112/75 (87) ± 4/2(3) 1.1 ± 0.3 12 ± 3.4
Haloperidol 1.0 mg/kg 62 95/45 (62) 1.2 25
80 88/47 (61) 1.9 23
71 ± 6 91/46(62) ± 2/1(1) 1.6 ± 0.2 24 ± 0.7
HR: Heart rate, BP: Arterial blood pressure (systolic/diastolic (mean)), VF: ventricular fibrillation.
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models [25].
In our experiments, high dose haloperidol prolonged MAPD90
compared to control. The AMI induced MAPD90 shortening in the
infarcted area was comparable in low dose, high dose and control
group. However, experiments on explanted papillary muscles from
guinea pigs suggest that ischemia induced shortening of APD canDownloaded for Anonymous User (n/a) at BS - University of Co
For personal use only. No other uses without permissiobe partially prevented with haloperidol [27]. We observed a trend
towards higher RV-LV dispersion in repolarization with haloperi-
dol before AMI was induced, as previously described in Langen-
dorff perfused rat hearts, where haloperidol increased local
dispersion of repolarization [28], that resolved during AMI.
Thomsen et al. suggested that BVR, a measure of temporal
dispersion of repolarization, might be of even greater importance
in predicting TdP than QT prolongation [12,29]. In our study, BVR
(measured as STV) increased slightly immediately after high dose
haloperidol was administered. However, STV was not different
between the groups before AMI induction or upon AMI, although
AMI itself increased STV.
PVCs during AMI occur in distinct phases with an early (1a)
and a later phase (1b) that can be identified within the first
30 min [9]. As we found VF to arise exclusively in the first
30 min in the porcine AMI model, we focused on phase 1a and
1b arrhythmias. No differences in PVCs with haloperidol in phase
1a could be observed, while PVCs in phase 1b were reduced in the
high dose group. Arrhythmias in phase 1b are linked to cate-
cholamine levels in the infarcted area and blockage of a1-
adrenergic receptor reduced ventricular arrhythmias [30].
Haloperidol has antagonistic a1-adrenergic receptor properties
that could potentially explain the trend towards antiarrhythmic
effects observed. Mow et al. reported anti-arrhythmic effects of
antipsychotic drugs that depend on their potency of a1-
adrenergic receptor affinities [31].penhagen from ClinicalKey.com by Elsevier on May 01, 2020.
n. Copyright ©2020. Elsevier Inc. All rights reserved.
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haloperidol treatment. The dominant frequency of VF was reduced
with high dose haloperidol, suggesting slowing in ventricular repo-
larization and/or conduction.
4.3. Hemodynamic effects
We observed a dose-dependent reduction in arterial blood pres-
sure after haloperidol infusion that was further aggravated during
AMI in the high dose group. As CO and EF was comparable between
all three groups, the decrease in blood pressure was due to
decreased SVR. The a1-adrenergic receptor antagonistic effects of
haloperidol resulted in blood pressure drop as previously described
[17,18]. Hence, it can be speculated that the reduction in cardiac
afterload with haloperidol can reduce the work and oxygen con-
sumption of the infarcted heart and thereby have anti-
arrhythmic properties.
4.4. Limitations
All experiments were carried out in general anesthesia which
can have substantial effects on the autonomic system. Our study
investigated a single treatment with haloperidol administered an
hour before AMI. Effects of long-term drug intake or polypharmacy
was not studied. Long-term treatment could potentially alter ion-
channel expression to compensate for chronic hERG blockage or
weaken effects on SVR and blood pressure. We solely investigated
haloperidol in the setting of AMI, while treatment with the drug
during the days following AMI, when electrophysiology is different
or heart failure might be present, was not studied.
Changes in the electrophysiological parameters can differ
greatly between different regions of the heart. In our study, we
only used two MAP electrodes to measure changes in APD with
haloperidol and during AMI. Whole-heart mapping techniques
could provide further insights into electrical dispersion.
Plasma or tissue levels of haloperidol concentration were not
measured during the experiments. We did not measure infarct size
directly in our experiments but only used indirect markers, like
STVM. However, to ensure an equally distributed infarct size the
occlusion was performed blinded in regard to treatment group.
Experiments were performed in a porcine model of acute ische-
mia. This model is well established in our group and widely used in
ischemia research, although with differences in the conduction
system compared to humans [23]. Furthermore the use of dogs is
fairly restricted at our research institution. Research on TdP has
predominantly been carried out in guinea pigs, rabbits and dogs,
while porcine models have been used rarely, making comparison
to other studies more difficult [25,32].5. Conclusion
Haloperidol, administered before AMI, did not lead to a higher
incidence of VF in our porcine model. With regard to hemodynamic
parameters, we observed a reduced SVR leading to a reduction in
blood pressure with haloperidol treatment. Although high dose
haloperidol treatment led to prolonged QT intervals, no TdP was
induced by PVCs. Further, we saw a significant reduction in num-
ber of PVCs in phase 1b.
We could not identify an increased risk of VF and subsequent
SCD during AMI in pigs treated with the antipsychotic drug
haloperidol. Haloperidol’s a1-adrenergic receptor blocking effect
with subsequent reduced cardiac afterload might counterbalance
the potential arrhythmic effects of hERG channel blockage in this
setting. It could be argued that this blockage in combination with
a mild QT prolongation is protective of VF in the early phase ofDownloaded for Anonymous User (n/a) at BS - University of Copen
For personal use only. No other uses without permission. CAMI. Of course this needs further pre-clinical testing. Our study
does not suggest that AMI might contribute to the excess mortality
in patients treated with antipsychotic drugs as seen in epidemio-
logical studies. However, further studies, including long-term
haloperidol treatment before AMI is induced and haloperidol treat-
ment during the days following AMI, are needed.
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